Proteomedix appoints Helge Lubenow as new CEO
Zurich-Schlieren, Switzerland, January 10, 2020. Proteomedix, a swiss diagnostics company committed to advance prostate cancer care announced today that its board of directors has appointed Helge Lubenow as Chief Executive Officer effective January 1, 2020. Helge will succeed Ralph Schiess, co-founder of Proteomedix who is transitioning to a newly established CSO role.
“Proteomedix is strongly positioned to greatly improve prostate cancer diagnostic triage and Helge is the ideal person to shape the company`s transformation to a commercial stage organization. Helge brings over 20 years of diagnostics industry experience and has a proven track record driving value creation in cancer diagnostics” commented Werner Schäfer, Chairman of the Board of Directors of Proteomedix.
“I am very excited to lead Proteomedix,” said Helge Lubenow. “The company is uniquely positioned to play a major role in non-invasive cancer detection and I am thrilled to have the opportunity to build a leading commercial organization and accelerate market adoption of its tests.”
“It has been a great journey leading Proteomedix from its inception to commercial entry” said Ralph Schiess. “Our biomarker signatures have the potential to change the way prostate cancer is being diagnosed. I am very pleased to welcome Helge to our mission to advance innovative diagnostics solutions and decrease the burden of cancer.”
Helge Lubenow ideally complements the management team including Christian Brühlmann COO/ CFO and Ralph Schiess CSO who co-founded Proteomedix and translated the original biomarker panel into a CE-IVD marked and market-ready product. She brings a wealth of leadership and operating experience to Proteomedix. She founded a consulting practice in 2015 and currently serves on the board of directors of several companies including Epigenomics AG, Indical Biosciences and Human Gesellschaft für Biochemika und Diagnostika. From 1997 to 2015 she was with QIAGEN, where she most recently led the diagnostics division as Senior Vice President Molecular Diagnostics. She holds a Ph.D. degree in Genetics from the University of Cologne, Germany.
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnostics. The company has identified novel biomarker signatures with utility in prostate cancer diagnostics, prognostics and therapy management. Their lead product Proclarix® is a blood based prostate cancer test panel and risk score and will be introduced to the market early 2020. Proteomedix is located in the Biotechnopark of Schlieren, Switzerland. For more information, visit www.proteomedix.com.